Related Experiment Video

Updated: Feb 13, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.7K

Abiraterone acetate in the treatment of prostate cancer

Abhimanyu Thakur1, Aishwarya Roy1, Arijit Ghosh2

  • 1Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology Mesra, India.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|March 2, 2018
PubMed

Insights

Abiraterone acetate (AA) offers a new treatment for metastatic castration-resistant prostate cancer by inhibiting androgen synthesis. This review details its pharmacology, clinical use, and resistance mechanisms for prostate cancer patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Prostate cancer is a leading cause of cancer death in men.
  • Metastatic castration-resistant prostate cancer (mCRPC) poses treatment challenges due to continued androgen production.
  • Current treatments like androgen antagonists have limited efficacy in prolonging patient survival.

Purpose of the Study:

  • To provide a comprehensive pharmacological profile of abiraterone acetate (AA).
  • To review AA's mechanism of action, resistance, pharmacokinetics, clinical findings, and toxicity.
  • To discuss predictive markers and optimal treatment sequencing for AA in prostate cancer.

Main Methods:

  • Review of abiraterone acetate's selective inhibition of CYP17 enzymes (17α-hydroxylase and C17, 20-lyase).
  • Analysis of androgen receptor signaling pathways in prostate cancer progression.
  • Compilation of data on clinical efficacy, pharmacokinetics, and safety of AA.

Main Results:

  • Abiraterone acetate effectively inhibits androgen synthesis essential for prostate cancer growth.
  • The review covers AA's mechanism of action, resistance, pharmacokinetics, and clinical outcomes.
  • Toxicity, food interactions, and predictive markers are discussed for optimal patient management.

Conclusions:

  • Abiraterone acetate represents a significant advancement in treating metastatic castration-resistant prostate cancer.
  • Understanding AA's profile aids in optimizing treatment strategies and managing resistance.
  • Further research into predictive markers and treatment sequences will enhance its clinical utility.
Keywords:
Abiraterone acetateCancerProstateTherapeutics

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K
Focal Laser Ablation of Prostate Cancer: An Office Procedure11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Acetals and Thioacetals as Protecting Groups for Aldehydes and Ketones01:24

Acetals and Thioacetals as Protecting Groups for Aldehydes and Ketones

Acetals are formed by reacting two equivalents of alcohol with carbonyl compounds like aldehydes or ketones. Acetals are unaffected by bases, nucleophiles, oxidizing agents, and reducing agents. They serve as protecting groups for aldehydes and ketones. Acetals can be easily formed and also easily removed via mild acid hydrolysis.
In the presence of multiple functional groups, when selective reduction of one group over the other is desired, groups like aldehydes and ketones that form acetals...
5.9K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
981